While both vaccines were highly immunogenic, eliciting high-titer antibody responses against their respective target in the vaccinated animals, only the Qβ-PHF1 vaccine was able to reduce tau pathology and rescue cognitive deficits. The gene discussed is MAPT; the disease is Cognitive impairment.